2025-12-30 - Analysis Report
Here's a comprehensive analysis of UnitedHealth Group (UNH) based on the provided data, structured for clarity.

**0. Overview**

*   **Ticker:** UNH
*   **Company Name:** UnitedHealth Group Inc
*   **Overview:**  UnitedHealth Group is a diversified health care company providing a wide range of products and services, such as health insurance and healthcare technology.

**1. Return Rate Comparison**

*   **UNH Cumulative Return:** -17.298%
*   **VOO (S&P 500) Cumulative Return:** 103.210%
*   **Divergence:** -119.3
*   **Relative Divergence:** 6.8 (Near the bottom of its historical divergence range).

**Analysis of Alpha/Beta Table:**

The table provides insights into UNH's performance relative to the market over rolling 3-year periods.  Key observations:

*   **2015-2017 to 2017-2019:** Strong CAGR, positive Alpha, and low Beta (around 0.1-0.2) indicating outperformance and low market sensitivity.
*   **2018-2020 to 2023-2025:** The CAGR significantly decreases, with negative Alphas suggesting underperformance relative to the market.  Beta increases, especially in 2019-2021 and 2023-2025 indicating higher market sensitivity.
*   **MDD:**  Maximum Drawdown remains high across all periods, indicating significant potential losses.
*   **Cap(B):**  Market capitalization consistently increased over the years, reflecting the growth of the company. However, it decreased in the last period.

**Conclusion:** In recent years, UNH has significantly underperformed the S&P 500. The rising Beta suggests increased correlation with market volatility, which it was not before. 
**2. Recent Stock Price Fluctuations**

*   **Current Close:** 331.8299865722656
*   **Last Market Data:** Price: 328.94, Previous Close: 331.83, Change: -0.87
*   **5-day SMA:** 327.358
*   **20-day SMA:** 330.706
*   **60-day SMA:** 338.8677

**Analysis:**

The stock price is currently below its 20-day and 60-day SMAs, suggesting a short-term downtrend. The 5-day SMA is also below the 20-day SMA, reinforcing this trend.

**3. RSI, PPO and Market Risk Indicators**

*   **MRI:** 0.9 (Medium to High Investment Recommended)
*   **RSI:** 50.93 (Neutral)
*   **PPO:** -0.0162 (Slightly Negative)
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (2 shares - Safe - MRI:0.80) Dividend_2.21 (Cash Ratio: 0% on 2025-12-08)
*   **Recent (20 days) relative divergence change:** -2.3 (Indicates short-term decline)
*   **Expected Return (%):** -283.7 (Significantly Negative)

**Analysis:**

*   The MRI suggests medium-to-high investment opportunity, while the RSI is neutral, indicating that the stock is neither overbought nor oversold.
*   The negative PPO indicates that UNH's short-term moving average is slightly below its long-term moving average, suggesting a potential bearish trend.
*   The hybrid signal recommends a strong buy with no cash on hand, while the Expected Return is significantly negative, meaning that the stock is expected to dramatically drop compared to S&P 500 (VOO).

**4. Recent News & Significant Events**

*   **Negative News:** The WSJ flagged Optum mail-order refills, which could affect future guidance.
*   **Positive/Neutral News:** Several articles highlight UNH as undervalued, a blue-chip stock with growth potential, and predict future stock increases (e.g., in 2026).  There are also reports of institutional investment.
*   **Regulatory Scrutiny:** There are opinions on audit reforms and regulatory scrutiny related to UNH.

**Analysis:**

The news is mixed.  Concerns regarding Optum are a near-term headwind. However, the recurring sentiment that UNH is undervalued, alongside forecasts of future growth, provides a counterpoint. Regulatory scrutiny, as mentioned in the news headlines, is also something to keep in mind.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (~1.96 on a 1-5 scale)
*   **Opinions:** 25
*   **Target Price (Avg/High/Low):** 392.24 / 440.00 / 280.00

**Analysis:**

Analysts, on average, have a positive outlook on UNH, with a "Buy" consensus and a substantial average target price above the current price. This indicates potential upside, but note the wide range between the high and low target prices.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue        |
| ----------- | ---- | -------------- |
| 2025-10-28 | 2.59 | 113.16 B$      |
| 2025-08-11 | 3.76 | 111.62 B$      |
| 2025-05-07 | 6.9  | 109.58 B$      |
| 2024-11-04 | 6.56 | 100.82 B$      |
| 2025-10-28 | 6.56 | 100.82 B$      |

**Analysis:**

*   Revenue has generally increased over the last few quarters, indicating business growth. However, the most recent EPS (2025-10-28) is significantly lower than previous quarters.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue     | Profit Margin |
| ---------- | ----------- | --------------- |
| 2025-09-30 | $113.16B   | 18.24%          |
| 2025-06-30 | $111.62B   | 17.93%          |
| 2025-03-31 | $109.58B   | 21.70%          |
| 2024-12-31 | $100.81B   | 21.14%          |
| 2024-09-30 | $100.82B   | 22.84%          |

**Capital and Profitability:**

| Quarter    | Equity      | ROE      |
| ---------- | ----------- | -------- |
| 2025-09-30 | $95.79B   | 2.45%    |
| 2025-06-30 | $94.72B   | 3.60%    |
| 2025-03-31 | $95.04B   | 6.62%    |
| 2024-12-31 | $92.66B   | 5.98%    |
| 2024-09-30 | $94.53B   | 6.41%    |

**Analysis:**

*   Revenue continues to climb. However, profit margin has decreased in the most recent quarter compared to the start of 2025.
*   Equity has increased slightly over the periods.
*   Return on Equity (ROE) has decreased significantly in recent quarters. This suggests that UNH is generating less profit per dollar of equity than it was previously.

**7. Comprehensive Analysis Summary**

*   **Negative Returns:** UNH has significantly underperformed the S&P 500 recently.
*   **Technical Indicators:** Short-term downtrend is evident based on SMAs, with neutral RSI and slightly negative PPO.
*   **Mixed News:** Negative news about Optum's mail-order refills is countered by the sentiment that the stock is undervalued and potential growth.  Regulatory scrutiny is a factor.
*   **Analyst Optimism:** Analysts have a "Buy" consensus, with a target price higher than the current price.
*   **Declining Profitability:** While revenues are up, EPS, Profit Margin, and ROE have declined, indicating a potential weakening of profitability.
*   **Risk:** The high Maximum Drawdown and increased beta indicate significant potential for losses and a higher correlation to market volatility.

**Overall Recommendation:**

The outlook for UNH is uncertain. While analysts are optimistic and revenue is growing, declining profitability metrics and potential headwinds from Optum suggest caution. Furthermore, while MRI indicates a medium to high investment opportunity, the Expected Return is significantly negative. Potential investors should carefully weigh the risks and positive analyst outlook before making a decision.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.